Taken together, these data demonstrate that PSMA-DMAb can exert a profound therapeutic effect on a PSMA-expressing tumor in vivo, supporting the possible application of this therapy for the treatment of prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.